EGFR and renal cell carcinoma: Overall, the above study suggests the potential of combining targeted EGFR NK-92 cells with small-molecule inhibitors, such as cabozantinib, to enhance treatment outcomes in kidney cancer, offering a promising therapeutic approach for RCC patients.